门诊静脉切除术中持续抗凝不影响术后出血风险
本机构在门诊静脉切除术(AP)中持续抗凝。研究纳入2016年1月至2023年2月需AP的患者,倾向性评分匹配70对。持续抗凝组术后出血2.9% vs 0%、显著瘀斑4.5% vs 1.5%、严重疼痛1.4% vs 0%、蜂窝织炎1.4% vs 0%,均无显著差异;无30天急诊就诊或主要不良心脏事件。
要点
- 持续抗凝患者AP术后出血2.9% vs 0%,无显著差异(P > .05)。
- 显著瘀斑4.5% vs 1.5%(P = .671),严重疼痛1.4% vs 0%,均无显著差异。
- 无30天急诊就诊或主要不良心脏事件,继续抗凝可能安全。
核心结论
- 持续慢性抗凝下进行AP未导致出血率、急诊就诊或主要不良事件增加。
- 在这些门诊手术中持续抗凝可能是安全的。
研究设计与样本
- 研究纳入2016年1月至2023年2月四个门诊办公室需AP的全部患者1853例,其中101例(5.5%)接受慢性抗凝。
- 慢性抗凝定义为索引手术前≥30天使用抗凝且未在手术期间停药。
- 采用16项人口学参数进行倾向性评分匹配,每组70例匹配。
主要发现
- 匹配后持续抗凝组术后出血2.9% vs 非抗凝组0%(P > .05)。
- 显著瘀斑4.5% vs 1.5%(P = .671)。
- 随访严重疼痛1.4% vs 0%(P > .05)。
- 术后蜂窝织炎1.4% vs 0%(P > .05)。
- 无术中主要出血事件,无30天急诊就诊或主要不良心脏事件。
临床怎么用
- 本研究中心的做法是门诊静脉切除术期间持续抗凝。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic anticoagulation for atrial fibrillation, a history of venous thromboembolism, and after heart valve replacement is often stopped or bridged for surgery. Our institutional practice is to continue anticoagulation through ambulatory phlebectomy (AP) procedures. As such, we aimed to compare postprocedure bleeding and major adverse events in patients on anticoagulation who received AP compared with patients not on anticoagulation. METHODS: We included all patients who required AP from January 2016 to February 2023. Given the low frequency of chronic anticoagulation during the study period, as defined as patients on anticoagulation ≥30 days before index procedure and not held through the procedure, a propensity score match of 16 demographic parameters was performed to better match patients. After propensity matching, we compared the frequency and quality of postprocedural bleeding (none, incisional, large volume), extent of postprocedural ecchymosis (none, minimal, moderate, significant), and pain (minimal, moderate, severe) on follow-up examination with a provider. Thirty-day emergency department (ED) visits and major adverse cardiac events were also recorded for each patient. Continuous variables were compared using independent t tests or Mann-Whitney U tests, and categorical variables were compared using a χ2 or Fisher's exact test. RESULTS: In total, 1853 patients received AP from four outpatient offices during the study period, 101 (5.5%) of whom were on chronic anticoagulation. Seventy patients for each group were propensity score matched in key demographics including age, gender, body mass index, Clinical-Etiology-Anatomy-Pathophysiology classification, prior vein procedures, concomitant laser procedures, number of phlebectomies performed, and comorbidities like history of deep vein thrombosis, pulmonary embolism, and peripheral arterial disease. There were no intraoperative major bleeding events. Patients on chronic anticoagulation were not more likely to have increased postprocedural bleeding (2.9% vs 0%; P > .05), significant ecchymosis (4.5% vs 1.5%; P = .671), severe pain on follow-up (1.4% vs 0%; P > .05), or increased likelihood of postprocedural cellulitis (1.4% vs 0%; P > .05). There were no instances of 30-day ED visits or major adverse cardiac events. Within patients on anticoagulation, use of rivaroxaban (8%) had higher incidence of bleeding than those on apixaban or warfarin (0%); however, these findings were not significant. CONCLUSIONS: AP while continuing chronic anticoagulation did not result in an increased rate of bleeding, ED visits, or major adverse events. It is likely safe to continue anticoagulation throughout these outpatient procedures.
引用
- Cleary CM, Orosco E, Gallagher J, et al. Continuation of anticoagulation through ambulatory phlebectomy does not impact postoperative bleeding risk. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 39890080. doi:10.1016/j.jvsv.2025.102199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。